Muscarinic M1/M4 receptor (agonist/antagonist combination)

Class

Xanomeline-trospium (M1/M4 agonist + peripheral antimuscarinic)

Muscarinic receptors are a family of five G-protein-coupled receptors (M1 through M5) activated by the neurotransmitter acetylcholine throughout the central and peripheral nervous systems. The M1 and M4 subtypes are enriched in brain regions involved in cognition, attention, and the regulation of dopamine signaling, making them long-standing targets for conditions such as psychosis and cognitive impairment. Directly stimulating these receptors with an agonist can modulate neural circuits implicated in schizophrenia without relying on the dopamine-receptor blockade used by conventional antipsychotic drugs, offering a mechanistically distinct approach. However, acetylcholine also acts on muscarinic receptors outside the brain—in the gut, bladder, heart, and salivary glands—so a systemically active agonist tends to produce gastrointestinal, cardiovascular, and secretory side effects. Pairing a brain-penetrant M1/M4 agonist with a peripherally restricted muscarinic antagonist is a strategy designed to blunt these unwanted peripheral effects while preserving the intended central nervous system activity. This combination approach illustrates a broader pharmacological principle: pairing an active agent with a counterbalancing agent that is confined to one body compartment can improve the tolerability of a drug whose therapeutic target and side-effect-generating receptors are the same molecular family but located in different tissues.